Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction

医学 心力衰竭 射血分数 内科学 安慰剂 心脏病学 临床终点 射血分数保留的心力衰竭 不利影响 随机对照试验 心率 血压 病理 替代医学
作者
James E. Udelson,Gregory D. Lewis,Sanjiv J. Shah,Michael R. Zile,Margaret M. Redfield,John C. Burnett,John D. Parker,Jelena Seferović,Phebe Wilson,Robert S. Mittleman,Albert T. Profy,Marvin A. Konstam
出处
期刊:JAMA [American Medical Association]
卷期号:324 (15): 1522-1522 被引量:127
标识
DOI:10.1001/jama.2020.16641
摘要

Importance: Heart failure with preserved ejection fraction (HFpEF) is often characterized by nitric oxide deficiency. Objective: To evaluate the efficacy and adverse effects of praliciguat, an oral soluble guanylate cyclase stimulator, in patients with HFpEF. Design, Setting, and Participants: CAPACITY HFpEF was a randomized, double-blind, placebo-controlled, phase 2 trial. Fifty-nine sites enrolled 196 patients with heart failure and an ejection fraction of at least 40%, impaired peak rate of oxygen consumption (peak V̇o2), and at least 2 conditions associated with nitric oxide deficiency (diabetes, hypertension, obesity, or advanced age). The trial randomized patients to 1 of 3 praliciguat dose groups or a placebo group, but was refocused early to a comparison of the 40-mg praliciguat dose vs placebo. Participants were enrolled from November 15, 2017, to April 30, 2019, with final follow-up on August 19, 2019. Interventions: Patients were randomized to receive 12 weeks of treatment with 40 mg of praliciguat daily (n = 91) or placebo (n = 90). Main Outcomes and Measures: The primary efficacy end point was the change from baseline in peak V̇o2 in patients who completed at least 8 weeks of assigned dosing. Secondary end points included the change from baseline in 6-minute walk test distance and in ventilatory efficiency (ventilation/carbon dioxide production slope). The primary adverse event end point was the incidence of treatment-emergent adverse events (TEAEs). Results: Among 181 patients (mean [SD] age, 70 [9] years; 75 [41%] women), 155 (86%) completed the trial. In the placebo (n = 78) and praliciguat (n = 65) groups, changes in peak V̇o2 were 0.04 mL/kg/min (95% CI, -0.49 to 0.56) and -0.26 mL/kg/min (95% CI, -0.83 to 0.31), respectively; the placebo-adjusted least-squares between-group difference in mean change from baseline was -0.30 mL/kg/min ([95% CI, -0.95 to 0.35]; P = .37). None of the 3 prespecified secondary end points were statistically significant. In the placebo and praliciguat groups, changes in 6-minute walk test distance were 58.1 m (95% CI, 26.1-90.1) and 41.4 m (95% CI, 8.2-74.5), respectively; the placebo-adjusted least-squares between-group difference in mean change from baseline was -16.7 m (95% CI, -47.4 to 13.9). In the placebo and praliciguat groups, the placebo-adjusted least-squares between-group difference in mean change in ventilation/carbon dioxide production slope was -0.3 (95% CI, -1.6 to 1.0). There were more dizziness (9.9% vs 1.1%), hypotension (8.8% vs 0%), and headache (11% vs 6.7%) TEAEs with praliciguat compared with placebo. The frequency of serious TEAEs was similar between the groups (10% in the praliciguat group and 11% in the placebo group). Conclusions and Relevance: Among patients with HFpEF, the soluble guanylate cyclase stimulator praliciguat, compared with placebo, did not significantly improve peak V̇o2 from baseline to week 12. These findings do not support the use of praliciguat in patients with HFpEF. Trial Registration: ClinicalTrials.gov Identifier: NCT03254485.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
cdercder的应助被Safe采纳,获得10
1秒前
2秒前
爱卿5271完成签到,获得积分10
2秒前
2秒前
Magic麦发布了新的文献求助10
2秒前
2秒前
3秒前
3秒前
小张爱科研完成签到 ,获得积分10
3秒前
天天快乐的应助被子木采纳,获得10
3秒前
CipherSage的应助被wwwwwwww采纳,获得10
3秒前
希望天下0贩的0的应助被123采纳,获得10
4秒前
扶风阁主完成签到,获得积分10
4秒前
三月兔发布了新的文献求助10
4秒前
4秒前
爆米花的应助被桃子采纳,获得10
4秒前
明理鸿发布了新的文献求助10
4秒前
CodeCraft的应助被红颜刹朱槿采纳,获得10
5秒前
5秒前
糊涂的中恶完成签到,获得积分10
6秒前
彭于晏发布了新的文献求助10
6秒前
洛玥发布了新的文献求助10
6秒前
7秒前
7秒前
zrf发布了新的文献求助100
8秒前
李健的粉丝团团长的应助被mjq采纳,获得10
8秒前
NexusExplorer的应助被ECCE采纳,获得10
8秒前
牧木完成签到,获得积分10
8秒前
影逐光发布了新的文献求助10
8秒前
9秒前
传奇3的应助被hahage采纳,获得50
9秒前
精明梦柏完成签到,获得积分10
9秒前
9秒前
核桃发布了新的文献求助10
9秒前
勇猛的小qin完成签到 ,获得积分10
9秒前
冷酷的问梅完成签到,获得积分10
10秒前
科研通AI2S的应助被curry采纳,获得10
10秒前
自信谷冬发布了新的文献求助10
10秒前
宁灭龙发布了新的文献求助10
10秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8155737
求助须知:如何正确求助?哪些是违规求助? 9552018
关于积分的说明 21707687
捐赠科研通 7744923
什么是DOI,文献DOI怎么找? 3426177
关于科研通互助平台的介绍 2551229
邀请新用户注册赠送积分活动 2469949